



Please complete the following questions if requesting nursing or pharmacy credit.

**The Role of Systemic Chemotherapy in Prostate Cancer:  
Maximizing Clinical Outcomes Webcast**

*POST-TEST*

1. In the TAX 327 trial, the median survival benefit of 19.2 months was seen in which study arm?
  - a) Docetaxel q 3 weeks plus daily prednisone
  - b) Docetaxel q 1 week plus daily prednisone
  - c) Mitoxantrone q 3 weeks plus daily prednisone
  
2. Locally recurrent prostate cancer is associated with a significant risk of disease progression:
  - a) True
  - b) False

\_\_\_\_\_  
**Name**

\_\_\_\_\_  
**Degree**

\_\_\_\_\_  
**Date Completed**